Table 3.

Cox regression analysis: atherosclerotic events/death

VariableUnivariate AnalysisAdjustment for eGFR and ln AlbuminuriaAdjustment for eGFR, ln Albuminuria, Age, and SexAdjustment for eGFR, ln Albuminuria, Age, Sex, Diabetes Mellitus, and CVDAdjustment for eGFR, ln Albuminuria, Age, Sex, Diabetes Mellitus, CVD, and CKD-MBDa Measures
HR (95% CI)P ValueHR (95% CI)P ValueHR (95% CI)P ValueHR (95% CI)P ValueHR (95% CI)P Value
ln sKlotho0.80 (0.40–1.58)0.520.89 (0.45–1.77)0.750.84 (0.44–1.62)0.610.67 (0.34–1.34)0.260.66 (0.33–1.31)0.24
PTH1.00 (1.00–1.01)0.0061.00 (1.00–1.00)0.941.00 (1.00–1.00)0.901.00 (1.00–1.01)0.901.00 (1.00–1.00)0.95
FePi 1.03 (1.02–1.05)<0.0011.01 (0.99–1.03)0.261.01 (0.98–1.03)0.661.00 (0.98–1.02)0.931.00 (0.98–1.03)0.86
Phosphate (mg/dl)1.31 (1.03–1.67)0.031.03 (0.77–1.37)0.841.04 (0.77–1.40)0.801.13 (0.83–1.55)0.441.12 (0.79–1.58)0.53
ln FGF-23 (rU/ml)1.50 (1.22–1.85)<0.0011.18 (0.90–1.56)0.241.14 (0.87–1.50)0.331.11 (0.86–1.44)0.411.11 (0.85–1.45)0.46
  • sKlotho (in pg/ml), albuminuria (in mg/g), and FGF-23 (in rU/ml) were ln-transferred because of skewed distribution. CVD, cardiovascular disease; CKD-MBD, CKD–mineral and bone disorders; HR, hazard ratio; 95% CI, 95% confidence interval; PTH, parathyroid hormone; FePi, urinary fractional phosphate excretion.

  • a ln sKlotho, PTH, FePi, phosphate and/or ln FGF-23, as appropriate